Novartis announced a $1.4 billion acquisition of Tourmaline Bio, securing rights to pacibekitug, a promising Phase 3-ready antibody targeting atherosclerotic cardiovascular disease. The drug aims to address systemic inflammation, a key factor in heart disease, potentially complementing existing cholesterol-focused treatments. Novartis's move follows positive Phase II data showing significant C-reactive protein reductions with a favorable safety profile. This strategic buy accelerates Novartis's push into cardiovascular disease, seeking to fill gaps in current therapies and diversify its portfolio.